New Therapies in Pain & Oncology

About Us


image-placeholder

Committed to improving pain management and cancer treatment outcomes

NovaPharm is a late stage drug development company focused on new treatments for Complex Regional Pain Syndrome and for skeletal related events due to solid tumors

image-placeholder

NPT-001: Complex Regional Pain Syndrome

Orphan drug, breakthrough designation, phase 3 (partnered)

image-placeholder

NPT-002: Metastatic Cancer

Novel oral therapy, metastatic breast cancer, Phase 3

Management Team


Michael Shine - CEO

Paul Silver PhD - Head R&D

Mike co founded NovaPharm in 2011 after 25+ years in the pharmaceutical, biotech and consumer products industries. The company has successfully partnered its lead program and is in phase 3 for its second asset.

Paul co founded NovaPharm and with over 30 years of experience in preclinical and clinical drug development, Paul has been instrumental in leading the successful development of the company's lead compounds.

Greg Hockel - Head of Regulatory

Marco Pappagallo MD - Medical Affairs and Scientific Advisory

Greg joined NovaPharm in 2016 bringing a wealth of regulatory experience across multiple therapeutic areas. Greg has been instrumental in establishing the regulatory path for NPT-002.

Marco was an original founding member of NovaPharm in 2011. He remains an active member of the Board and provides scientific and medical oversight to the company.

Michael Shine - CEO

Mike co founded NovaPharm in 2011 after 25+ years in the pharmaceutical, biotech and consumer products industries. The company has successfully partnered its lead program and is in phase 3 for its second asset.

Paul Silver PhD - Head R&D

Paul co founded NovaPharm and with over 30 years of experience in preclinical and clinical drug development, Paul has been instrumental in leading the successful development of the company's lead compounds.

Greg Hockel - Head of Regulatory

Greg joined NovaPharm in 2016 bringing a wealth of regulatory experience across multiple therapeutic areas. Greg has been instrumental in establishing the regulatory path for NPT-002.

Marco Pappagallo MD - Medical Affairs and Scientific Advisory

Marco was an original founding member of NovaPharm in 2011. He remains an active member of the Board and provides scientific and medical oversight to the company.

Contact Us


For Inquiries please complete the form below

Thank you for your interest in NovaPharm Therapeutics